Robert Whitfield MDAmerica's Breast Implant Illness Expert™

BIA-ALCL: Localized and Invasive Disease Do Not Behave the Same

1 Oct 2026 · 1 min

Watch on YouTube

0:36

In this brief presentation, Dr. Robert Whitfield explains that the World Health Organization officially recognized breast‑implant associated anaplastic large‑cell lymphoma (BIA‑ALCL) in 2016. He distinguishes two clinical patterns: when the disease is limited to a seroma (effusion) or the surrounding capsule, it follows a slow, indolent course with an excellent prognosis; whereas a subset of cases shows capsular invasion or a solid mass, behaves aggressively, and can be fatal. Although the aggressive form is rare, it is serious, and both patterns can coexist in the same disease spectrum.

Chapters

The World Health Organization formally recognized BIA-ALCL in 2016. When the disease is confined to the effusion, which is the fluid, or the capsule, it typically follows a very slow, indolent course, meaning it often behaves in a slow, like I said, more localized way. The prognosis is generally excellent. A subset will have capsular invasion or a mass that behaves more aggressively, and deaths have been reported. So this is uncommon, but it is very serious. Those 2 facts can sit together, of course.